[February 03, 2015]

Gastrointestinal Cancer Key Opinion Leader, Charles S. Fuchs, MD, MPH Joins, Enterade's Scientific Advisory Board

Enterade USA, an innovative health sciences company, announced today that Charles S. Fuchs, MD, MPH has joined as a member of the Company's esteemed Scientific Advisory Board. Dr. Fuchs is an internationally recognized expert in gastrointestinal oncology and he currently serves as the Chief of the Gastrointestinal Oncology Division at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer.

"It is an honor and a privilege to welcome Dr. Fuchs to Enterade's Scientific Advisory Board," commented Stephen J. Gatto, Chairman and Chief Executive Officer for Enterade USA. "Dr. Fuchs' clinical oncology and cancer research expertise will be instrumental to our efforts to advance our amino acid-based HydroActive Technology™ platform for oncology and GI health with scientific and clinical rigor. We look forward to Dr. Fuchs' many contributions and his valuable guidance as we progress our commercial-stage products pipeline."

Dr. Fuchs splits his time between laboratory-based research, clinical research, and clinical care. Dr. Fuchs leads the Dana-Farber Harvard Cancer Center (DF/HCC) Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers. He has also served as the extramural leader for the NCI-sponsored Genome-Wide Association Study in Pancreatic Cancer (PanScan). Dr. Fuchs' laboratory focuses on the role of nutrition in cancer risk and survival, biochemical and molecular predictors of cancer prognosis, and the discovery o novel targets for cancer therapy. Dr. Fuchs has led numerous national and international clinical trials assessing novel targeted therapies for GI malignancies.

Dr. Fuchs is a member of the Scientific Advisory Board for the Lustgarten Foundation for Pancreatic Cancer and a member of National Cancer Institute GI Cancer Steering Committee. Dr. Fuchs has over 450 scientific publications in such journals as The New England Journal of Medicine, Journal of the American Medical Association, Lancet, Journal of Clinical Oncology, Cell, and Nature.

Dr. Fuchs graduated honors, summa cum laude with his undergraduate degree from the University of Pennsylvania. Dr. Fuchs earned his medical degree from the Harvard Medical School and his master's degree in Public Health from the Harvard School of Public Health.

Dr. Fuchs joins other notable members of Enterade's Scientific Advisory Board including:

• Henry J. Binder, MD,: Chairman of the Scientific Advisory Board, Professor Emeritus of and Senior Research Scientist in Medicine (Digestive Diseases), Yale School of Medicine
• Dr. Gary R. Morrow, Ph.D. MS - Professor of Radiation Oncology, Professor of Psychiatry, University of Rochester Medical Center
• Sadasivan Vidyasagar, MD, PhD - Founder, Enterade USA, Assistant Professor, Department of Radiation Oncology, University of Florida
• Paul Okunieff, MD - Founder, Enterade USA, Professor and Chair, Department of Radiation Oncology, University of Florida
• Daniel B. Dennison, Ph.D., Chief Technology Officer, Enterade USA

About Enterade USA
Enterade USA is an innovative health sciences company that is advancing patient care and wellness through pharmaceutical and nutritional sciences. Our research and seminal discoveries led to the development of Enterade^®, a first-in-class carbohydrate-free food that reduces dehydration to help manage the side effects of cancer therapy. These discoveries also serve as the foundation for our pioneering HydroActive Technology™ platform which we are advancing for broad use including as a functional food to promote GI health, as a therapeutic for the treatment of cystic fibrosis, as well as a point-of-care diagnostic to measure radiation toxicity for people being treated for cancer. For more information, please visit us at www.enterade.com or on FaceBook at Enterade.

[ Back To TMCnet.com's Homepage ]